Proteoglycan degrading mutants for treatment of CNS

Details for Australian Patent Application No. 2004247026 (hide)

Owner Acorda Therapeutics, Inc.

Inventors D'Souza, Rohini; Gruskin, Elliott A.; Caggiano, Anthony O.; Roy, Gargi

Agent Pizzeys

Pub. Number AU-B-2004247026

PCT Pub. Number WO2004/110360

Priority 60/471,300 16.05.03 US; 60/471,240 16.05.03 US; 60/471,239 16.05.03 US; 60/474,372 29.05.03 US

Filing date 17 May 2004

Wipo publication date 23 December 2004

Acceptance publication date 24 September 2009

International Classifications

A61K 31/00 (2006.01)

Event Publications

1 December 2005 PCT application entered the National Phase

  PCT publication WO2004/110360 Priority application(s): WO2004/110360

24 September 2009 Application Accepted

  Published as AU-B-2004247026

21 January 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004247027-Methods of delivering anti-restenotic agents from a stent

2004247025-Fusion proteins for the treatment of CNS